Erbitux Companion Test Approval Clears Path For Further Co-Development
This article was originally published in The Gray Sheet
Executive Summary
DakoCytomation expects reimbursement policies for ImClone's Erbitux colorectal cancer drug to guide adoption of companion diagnostic EGFR pharmDx